Cartesian Therapeutics, Inc. (RNAC): who owns it and who trades it
As of Nov 16, 2026, RNAC insiders reported 3 open-market sales worth $259K and 1 purchase worth $206K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Carsten Brunn (CEO), with $162K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cartesian Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RNAC
94 funds and institutions reported RNAC shares worth $90.7M at the end of Q2 2026, about 30% of the company. The largest holder is Squarepoint Ops LLC with 7.7%.
Funds and institutions (13F) 30%Everyone else 70%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Squarepoint Ops LLC | 2.25M | 7.67% | $23.5M | +1% |
| BlackRock, Inc. | 819,239 | 2.79% | $8.5M | +37% |
| 683 Capital Management, LLC | 650,000 | 2.21% | $6.8M | +97% |
| Vanguard Capital Management LLC | 555,823 | 1.89% | $5.8M | +36% |
| FMR LLC (Fidelity) | 368,429 | 1.25% | $3.8M | -54% |
| Geode Capital Management, LLC | 356,525 | 1.21% | $3.7M | +35% |
| AQR Capital Management LLC | 356,456 | 1.21% | $3.7M | +324% |
| Millennium Management LLC | 309,887 | 1.05% | $3.2M | +9% |
| Two Sigma Investments, LP | 296,293 | 1.01% | $3.1M | +77% |
| State Street Corp | 249,212 | 0.85% | $2.6M | +24% |
| Marshall Wace, LLP | 232,919 | 0.79% | $2.4M | -7% |
| UBS Group AG | 208,647 | 0.71% | $2.2M | +52% |
| Jupiter Topco LLC | 200,905 | 0.68% | $2.1M | New |
| Privium Fund Management B.V. | 151,675 | 0.52% | $1.6M | -15% |
| Northern Trust Corp | 105,698 | 0.36% | $1.1M | +15% |
| ADAR1 Capital Management, LLC | 98,877 | 0.34% | $1M | New |
| Vanguard Fiduciary Trust Co | 91,854 | 0.31% | $957K | +31% |
| Vanguard Portfolio Management LLC | 87,317 | 0.30% | $910K | +44% |
| Diadema Partners LP | 87,057 | 0.30% | $907K | New |
| Bank of America Corp | 84,624 | 0.29% | $882K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RNAC insiders reported $206K of open-market purchases and $259K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 6, 2026 | Carsten Brunn | CEO | Sale | 23,766 | $6.82 | $162K | Form 4 |
| Jan 6, 2026 | Milos Miljkovic | Chief Medical Officer | Sale | 3,573 | $6.82 | $24.4K | Form 4 |
| Jan 6, 2026 | Blaine Davis | CFO | Sale | 10,591 | $6.82 | $72.2K | Form 4 |
| Dec 4, 2025 | Timothy C Barabe | Director | Purchase | 30,000 | $6.86 | $206K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Timothy C Barabe | Director | $206K | – | Dec 4, 2025 |
| Carsten Brunn | President and CEO, Director | – | $162K | Jan 6, 2026 |
| Blaine Davis | Chief Financial Officer | – | $72.2K | Jan 6, 2026 |
| Milos Miljkovic | Chief Medical Officer | – | $24.4K | Jan 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RNAC short interest
Moderate short interest. 6.3% of RNAC shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.92M RNAC shares were sold short, 6.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 116,169 shares, buying them all back would take about 16.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.92M | 6.33% | +2% | 116,169 | 16.5 |
| Oct 15, 2026 | 1.88M | 6.20% | +1% | 159,823 | 11.7 |
| Sep 30, 2026 | 1.86M | 6.13% | +3% | 146,843 | 12.6 |
| Sep 15, 2026 | 1.80M | 5.96% | -0% | 106,105 | 17.0 |
| Aug 31, 2026 | 1.81M | 5.99% | -3% | 135,439 | 13.4 |
| Aug 14, 2026 | 1.87M | 6.17% | +1% | 104,625 | 17.9 |
| Jul 31, 2026 | 1.84M | 6.09% | -4% | 123,813 | 14.9 |
| Jul 15, 2026 | 1.93M | 6.55% | +2% | 156,524 | 12.3 |
| Jun 30, 2026 | 1.89M | 6.42% | -2% | 384,612 | 4.9 |
| Jun 15, 2026 | 1.93M | 6.56% | -16% | 594,373 | 3.2 |
| May 29, 2026 | 2.29M | 7.80% | +3% | 185,315 | 12.4 |
| May 15, 2026 | 2.22M | 7.54% | +2% | 186,619 | 11.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cartesian Therapeutics company events
Cartesian Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 29, 2026AnnouncementThe Company announced additional retreatment data from the Company’s Phase 2 trial of Descartes-08 in patients with MG. The data consisted of observations from five participants who experienced recurrence of MG symptoms (as measured by Myasthenia Gravis Activities of Daily Living ≥6) following… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- Jun 9, 2026AnnouncementShared information with investors. Filing
- May 26, 2026LeadershipMilos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company. Filing
- Apr 30, 2026ResultsReleased financial results. Filing
- Mar 30, 2026LeadershipMurat Kalayoglu, M.D., Ph.D., a member of the Board of Directors of Cartesian Therapeutics, Inc., notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities. Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
- Dec 18, 2025LeadershipThe Board of Directors of Cartesian Therapeutics, Inc. appointed Adrian Bot, M.D., Ph.D. as a Class II director. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cartesian Therapeutics financials
Famous investors that hold RNAC
4 of the 50 well-known investors we track reported holding RNAC in their latest 13F filing. The largest position is Israel Englander's, worth $1.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 221,858 | $1.6M | 0.0% | -28% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 72,200 | $521K | 0.0% | +256% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 70,005 | $505K | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 47,783 | $345K | 0.0% | +10% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RNAC in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 6, 2026 | Barclays PLC | 13G/A | 0.0% |
| Nov 6, 2026 | Barclays PLC | 13G/A | 0.0% |
Questions about Cartesian Therapeutics, Inc. (RNAC) stock
Who owns the most RNAC stock?
The largest reported owner of Cartesian Therapeutics, Inc. (RNAC) is Squarepoint Ops LLC, with 7.7% of the company. In total, 94 funds and institutions reported holding RNAC at the end of Q2 2026, together about 30% of the shares. See the largest owners.
Are RNAC insiders buying or selling?
In the last 12 months, RNAC insiders reported 1 open-market purchase worth $206K and 3 sales worth $259K. The latest trade was on Jan 6, 2026. See every trade.
What is the short interest in RNAC?
As of Oct 30, 2026, 1.92M RNAC shares were sold short, 6.3% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 116,169 shares, buying them all back would take about 16.5 trading days (days to cover). See the history.
Which famous investors hold RNAC?
4 of the 50 well-known investors we track reported RNAC in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $1.6M. See all holders.
Executive pay
Cartesian Therapeutics's chief executive was paid a total of $4.3M for the year ended Dec 31, 2025, down 41% from $7.3M the year before. In the last 12 months, Cartesian Therapeutics's executives and directors bought $206K of stock on the open market and sold $259K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.